+++++++++++++++++++++++++ DEAL EXPANDS THE BIOLOGICAL APPLICATIONS OF GRADIFLOW(TM) TECHNOLOGY
Gradipore (ASX: GDP) and Serologicals Corporation (Nasdaq: SERO) today announced a development agreement for evaluating the application of Gradipore's Gradiflow(TM) separations technology for the isolation of plasma proteins intended for use as diagnostic reagents, culture medium supplements, or for therapeutic indications. The agreement will generate immediate revenue for Gradipore.
Upon successful completion of the evaluation to the specified requirements of Serologicals, Gradipore and Serologicals will discuss a more extensive commercial agreement for the purification and commercialization of other plasma proteins.
"Mass producing medically-relevant products was the intention for the Gradiflow system, and we have the highest confidence that this agreement with Serologicals will clearly demonstrate this," said Gradipore CEO, Robert E Lieb. "Also of importance is the fact that this deal expands the diversity of biological applications for the Gradiflow technology."
"The Gradiflow technology offers an attractive alternative to the existing technologies of fractionation and chromatography with potentially higher yields at similar or superior quality," said David A. Dodd President and CEO of Serologicals Corporation. "Serologicals is excited to start this collaboration and have access to this promising platform in its continuous pursuit of the manufacture of the highest quality biologics."
For information on Gradipore, visit the company's corporate web site at www.gradipore.com.
ABOUT SEROLOGICALS CORPORATION
Serologicals Corporation, headquartered in Atlanta, Georgia, is a global provider of biological products and enabling technologies, which are essential for the research, development and manufacturing of biologically based life science products. The Company's products and technologies are used in a wide variety of innovative applications within the areas of oncology, hematology, immunology, cardiology and infectious diseases, as well as in the study of molecular biology. Serologicals has more than 650 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO.
For information on Serologicals Corporation, visit the company's corporate web site at www.serologicals.com
